Location of Repository

Potential cancer chemopreventive properties of resveratrol metabolites

By Ketan R. Patel

Abstract

Resveratrol (trans-3,5,4′-trihydroxystilbene), a naturally occurring polyphenol\ud present in grapes and red wine has undergone investigation as a potential\ud cancer chemopreventive agent. Resveratrol is rapidly and extensively\ud metabolised to its major phase II metabolites, including resveratrol sulfates and\ud glucuronides. It is not yet known whether resveratrol metabolites contribute to\ud the beneficial effects attributed to resveratrol, or whether resveratrol\ud regeneration can occur from the metabolites.\ud Resveratrol and metabolite pharmacokinetics were investigated in the plasma\ud of healthy human volunteers receiving 0.5, 1.0, 2.5 and 5.0 g resveratrol daily.\ud Concentrations were also quantified in malignant and non-malignant colon\ud tissue removed from colorectal cancer patients, who received 0.5 or 1.0 g\ud resveratrol daily. A mixture of resveratrol monosulfates and individual\ud monoglucuronide isomers were synthesised. Resveratrol monosulfates were\ud administered to mice to determine their pharmacokinetics. The effects of the\ud metabolites on proliferation in HCA-7, HT-29 and HCEC colon cell lines were\ud assessed.\ud In healthy volunteers, resveratrol metabolites were shown to be the major\ud species recovered from plasma. Average volunteer plasma AUClast for\ud resveratrol-4′-O-glucuronide and resveratrol-3-O-sulfate were approximately 36-\ud and 81-fold greater respectively than for resveratrol, following 0.5 g resveratrol\ud dosing. In colon tissues from cancer patients resveratrol generally\ud predominated, with resveratrol sulfate glucuronide being the most prominent\ud metabolite. In mice administered monosulfates, resveratrol formation was\ud found to occur, with measurable concentrations in plasma, mucosa, liver, lung\ud and pancreas. The conversion of resveratrol sulfates to resveratrol was also\ud observed in cells in vitro. Uptake of the metabolites and intracellular resveratrol\ud correlated with effects on proliferation. Whilst resveratrol monoglucuronides\ud had a limited inhibitory effect on cell proliferation, monosulfates caused a more\ud pronounced reduction, with the greatest effect in HT-29 followed by HCA-7\ud cells, and little or no effect in HCEC cells. Further investigations will improve\ud our understanding of the role of resveratrol metabolites in chemoprevention

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/9911

Suggested articles

Preview

Citations

  1. 3,3',4,5,5'-Pentahydroxy-trans-stilbene, a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress.
  2. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
  3. (1990). A genetic model for colorectal tumorigenesis.
  4. a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage.
  5. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
  6. A randomized trial of aspirin to prevent colorectal adenomas.
  7. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol.
  8. Absorption of three wine-related polyphenols in three different matrices by healthy subjects.
  9. Adjuvant therapy of colon cancer.
  10. (2003). Alcohol consumption, smoking, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev
  11. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies.
  12. An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster.
  13. and mouse metabolism of resveratrol.
  14. Anthocyanins and colonic metabolites of dietary polyphenols inhibit platelet function.
  15. Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol,
  16. Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets.
  17. Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes.
  18. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells.
  19. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation.
  20. Apple polyphenols affect protein kinase C activity and the onset of apoptosis in human colon carcinoma cells.
  21. (1993). Aspirin use and risk of fatal cancer.
  22. (1994). Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
  23. Assessment of resveratrol bioavailability in the perfused small intestine of the rat.
  24. (2008). autophagy, and cancer: a review. Cancer Epidemiol Biomarkers Prev
  25. Autophagy: assays and artifacts.
  26. (1995). Autres pays, autres coeurs? Dietary patterns, risk factors and ischaemic heart disease in Belfast and Toulouse. Qjm
  27. Between and within: international perspectives on cancer and health disparities.
  28. Bioactivity and metabolism of transresveratrol orally administered to Wistar rats.
  29. Bioavailability of trans-resveratrol from red wine in humans.
  30. Biological activity of resveratrol, a stilbenic compound from grapevines, against Botrytis cinerea, the causal agent for gray mold.
  31. Bradaschia A et al. Soluble polyphenols: synthesis and bioavailability of 3,4',5-tri(alpha-D-glucose-3-O-succinyl) resveratrol.
  32. (2006). Cancer Biology:
  33. (1995). Cancer Biology.
  34. Cancer chemoprevention with dietary phytochemicals.
  35. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.
  36. Cancer epidemiology in the last century and the next decade.
  37. Cell cycle and cancer.
  38. Cellular senescence in cancer and aging.
  39. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential.
  40. (1995). Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
  41. (2005). Chemoprevention of colorectal cancer: ready for routine use? Curr Top Med Chem
  42. Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis.
  43. (2002). Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev
  44. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells.
  45. (1996). cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting,
  46. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.
  47. Clinical trials of resveratrol.
  48. (2011). Clinical trials of resveratrol. Annals of the New York Academy of Sciences,
  49. (2008). Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos
  50. Colorectal cancer - the disease and its management.
  51. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
  52. (2001). Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog
  53. (2010). Comparison of [14C]-resveratrol pharmacokinetics and target tissue distribution in humans following a pharmacological and dietary dose using accelerator mass spectrometry (AMS). National Cancer Research Institute Annual Meeting
  54. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.
  55. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med 2000;29(12):1234-
  56. (2005). Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev
  57. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl.
  58. Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila)
  59. (1976). Cutaneous chemical carcinogenesis: past, present, and future.
  60. Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
  61. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
  62. Determination of dihydroresveratrol in rat plasma by HPLC.
  63. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila)
  64. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption.
  65. (1993). Diet and risk of colorectal adenomas: macronutrients, cholesterol, and fiber.
  66. Dietary intake and bioavailability of polyphenols.
  67. Dietary phenolics: chemistry, bioavailability and effects on health.
  68. Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen.
  69. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration.
  70. Distribution of [3H]trans-resveratrol in rat tissues following oral administration.
  71. Divergent effects of quercetin conjugates on angiogenesis.
  72. (1990). DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion.
  73. Dose escalation of a curcuminoid formulation.
  74. Dose response biology: the case of resveratrol.
  75. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med
  76. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines.
  77. Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer.
  78. Dynamics and diversity in autophagy mechanisms: lessons from yeast.
  79. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
  80. (1995). Effect of Enological Practices on the Resveratrol Isomer Content of Wine.
  81. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action.
  82. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis.
  83. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro.
  84. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation.
  85. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats.
  86. Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects.
  87. (1999). Emerging roles of caspase-3 in apoptosis.
  88. Falcao A et al. Pharmacokinetic and safety profile of transresveratrol in a rising multiple-dose study in healthy volunteers.
  89. Familial adenomatous polyposis in children and adolescents.
  90. Familial adenomatous polyposis.
  91. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liverspecific OATP-C.
  92. Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.
  93. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop.
  94. (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
  95. (1999). Gender-related differences in pharmacokinetics and their clinical significance.
  96. Genetic testing for high-risk colon cancer patients.
  97. (1992). Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients.
  98. (2000). Global cancer statistics in the year
  99. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver.
  100. (2011). Hepatic Glucuronidation of Resveratrol:
  101. (1998). High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence.
  102. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process.
  103. Human intestinal and lung cell lines exposed to beta-carotene show a large variation in intracellular levels of beta-carotene and its metabolites.
  104. Human sulfotransferases and their role in chemical metabolism.
  105. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS.
  106. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
  107. (1990). Increased cell division as a cause of human cancer.
  108. (1996). Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis.
  109. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression.
  110. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites.
  111. Insulin-like growth factor-I and cancer risk.
  112. (1994). Intake of fat, meat, and fiber in relation to risk of colon cancer in men.
  113. Interaction of dietary resveratrol with animal-associated bacteria.
  114. Investigation of piceid metabolites in rat by liquid chromatography tandem mass spectrometry.
  115. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice.
  116. Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells.
  117. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev
  118. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
  119. (1993). lysosomal enzymes, and cancer.
  120. Matrix effects on the bioavailability of resveratrol in humans.
  121. Mechanism-based in vitro screening of potential cancer chemopreventive agents.
  122. (2009). mediate cellular senescence induced by resveratrol in human endothelial cells. Free Radic Biol Med
  123. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.
  124. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
  125. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multiresistant protein 2 (MRP2) in flavonoid metabolism.
  126. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition.
  127. Molecular mechanism of the chemopreventive effect of resveratrol.
  128. Molecular targets of dietary agents for prevention and therapy of cancer.
  129. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats.
  130. Occurrence of resveratrol in edible peanuts.
  131. Olive oil, diet and colorectal cancer: an ecological study and a hypothesis.
  132. (2010). oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol
  133. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition.
  134. (2002). Ortega A et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med
  135. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
  136. (2010). Pharmacokinetic Study of transResveratrol in Adult Pigs. J Agric Food Chem
  137. Pharmacokinetics in mice and growthinhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.
  138. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects.
  139. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
  140. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
  141. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
  142. Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIHAARP Diet and Health Study. Cancer Causes Control
  143. Plant foods and herbal sources of resveratrol.
  144. Plasma metabolites of quercetin and their antioxidant properties.
  145. Plasmatic levels of trans-resveratrol in rats.
  146. Pleiotropic mechanisms facilitated by resveratrol and its metabolites.
  147. Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
  148. (2006). Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos
  149. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
  150. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma.
  151. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC.
  152. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography.
  153. Quantitative assay of senescence-associated beta-galactosidase activity in mammalian cell extracts.
  154. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway.
  155. Quinone reductase induction as a biomarker for cancer chemoprevention.
  156. (1997). Recent advances in chemoprevention of cancer.
  157. (2007). Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab Dispos
  158. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human.
  159. (2003). Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev
  160. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.
  161. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer.
  162. (2008). Resveratrol (trans-resveratrol, 3,5,4'-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos
  163. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.
  164. Resveratrol and resveratrol analogues--structure-activity relationship.
  165. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises.
  166. Resveratrol as an Inhibitor of Carcinogenesis.
  167. Resveratrol bioavailability and toxicity in humans.
  168. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.
  169. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro.
  170. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity.
  171. (2007). Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos
  172. Resveratrol induces apoptosis through ROSdependent mitochondria pathway in HT-29 human colorectal carcinoma cells.
  173. (2009). Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev
  174. Resveratrol inhibits firefly luciferase.
  175. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis.
  176. Resveratrol is absorbed in the small intestine as resveratrol glucuronide.
  177. Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and
  178. (2011). Resveratrol Metabolites Do Not Elicit Early Pro-apoptotic Mechanisms in Neuroblastoma Cells. J Agric Food Chem
  179. Resveratrol modulates drug- and carcinogenmetabolizing enzymes in a healthy volunteer study.
  180. Resveratrol prolongs lifespan and retards the onset of age-related markers in a shortlived vertebrate.
  181. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
  182. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism.
  183. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway.
  184. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation.
  185. Resveratrol transport and metabolism by human intestinal Caco-2 cells.
  186. Resveratrol-associated renal toxicity.
  187. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells.
  188. (1996). Resveratrol: Isomeric Molar Absorptivities and Stability.
  189. Resveratrolinduced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of autophagolysosomes.
  190. Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells.
  191. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells.
  192. Safety studies conducted on high-purity trans-resveratrol in experimental animals.
  193. Screening and diagnosis for colorectal cancer: present and future.
  194. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.
  195. Selenium compounds activate early barriers of tumorigenesis.
  196. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.
  197. (1998). Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans.
  198. Sirtuin activators mimic caloric restriction and delay ageing in metazoans.
  199. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.
  200. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain.
  201. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.
  202. (1999). Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharm Res
  203. Structure-activity relationship of trans-resveratrol and its analogues.
  204. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function.
  205. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1.
  206. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids.
  207. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2
  208. (1998). Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications.
  209. (1997). Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev
  210. Targeted metabolomics identifies glucuronides of dietary phytoestrogens as a major class of MRP3 substrates in vivo.
  211. (1992). The analgesic activity of morphine-6-glucuronide.
  212. The burden of cancer attributable to alcohol drinking.
  213. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.
  214. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today.
  215. The chemopreventive agent resveratrol stimulates cyclic AMP-dependent chloride secretion in vitro.
  216. The classification of cancer of the rectum.
  217. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
  218. The daily oral administration of high doses of transresveratrol to rats for 28 days is not harmful.
  219. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
  220. The hallmarks of cancer.
  221. the metabolic syndrome and cancer.
  222. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells.
  223. The role of folate, antioxidant vitamins and other constituents in fruit and vegetables in the prevention of cardiovascular disease: the epidemiological evidence.
  224. Therapy-induced senescence in cancer.
  225. Tissue distribution and excretion of resveratrol in rat after oral administration of Polygonum cuspidatum extract (PCE).
  226. To cycle or not to cycle: a critical decision in cancer.
  227. Toxicokinetics of resveratrol in dogs. Toxicology Letters 2007;172(Supplement 1):S102-S102.
  228. trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats.
  229. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake.
  230. treatment and chemoprevention in colorectal cancer.
  231. Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations.
  232. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry.
  233. Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.
  234. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice.
  235. (2004). Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos
  236. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.